MX2017006382A - Analogos de eter fosfolipidico como portadores de farmacos dirigidos a cancer. - Google Patents

Analogos de eter fosfolipidico como portadores de farmacos dirigidos a cancer.

Info

Publication number
MX2017006382A
MX2017006382A MX2017006382A MX2017006382A MX2017006382A MX 2017006382 A MX2017006382 A MX 2017006382A MX 2017006382 A MX2017006382 A MX 2017006382A MX 2017006382 A MX2017006382 A MX 2017006382A MX 2017006382 A MX2017006382 A MX 2017006382A
Authority
MX
Mexico
Prior art keywords
cancer
targeting drug
phospholipid ether
ether analogs
drug vehicles
Prior art date
Application number
MX2017006382A
Other languages
English (en)
Other versions
MX381235B (es
Inventor
P Weichert Jamey
Pinchuk Anatoly
Kozak Kevin
Longino Marc
Grudzinski Joseph
Titz Benjamin
Pak Chorom
Stehle Nathan
Original Assignee
Cellectar Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectar Biosciences Inc filed Critical Cellectar Biosciences Inc
Publication of MX2017006382A publication Critical patent/MX2017006382A/es
Publication of MX381235B publication Critical patent/MX381235B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6551—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring
    • C07F9/65512—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención está dirigida a compuestos terapéuticos capaces de dirigirse a células de cáncer y células madre de cáncer, la presente invención está además dirigida a composiciones que comprenden estos compuestos terapéuticos y métodos para tratar cáncer que comprenden administrar estos compuestos terapéuticos; un compuesto terapéutico que comprende la fórmula A-B-D en donde: A es al menos un compuesto de la fórmula (I).
MX2017006382A 2014-11-17 2015-11-06 Análogos de éter fosfolipídico como portadores de fármacos dirigidos a cáncer. MX381235B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462080436P 2014-11-17 2014-11-17
PCT/US2015/059382 WO2016081203A2 (en) 2014-11-17 2015-11-06 Phospholipid ether analogs as cancer-targeting drug vehicles

Publications (2)

Publication Number Publication Date
MX2017006382A true MX2017006382A (es) 2018-04-10
MX381235B MX381235B (es) 2025-03-12

Family

ID=55960741

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006382A MX381235B (es) 2014-11-17 2015-11-06 Análogos de éter fosfolipídico como portadores de fármacos dirigidos a cáncer.

Country Status (18)

Country Link
US (4) US9925269B2 (es)
EP (2) EP3750545B1 (es)
JP (1) JP6832861B2 (es)
KR (1) KR102500181B1 (es)
CN (2) CN107708702A (es)
AU (1) AU2015350400B2 (es)
BR (1) BR112017010188B1 (es)
CA (1) CA2968145C (es)
DK (2) DK3750545T3 (es)
EA (1) EA037519B1 (es)
ES (2) ES2811367T3 (es)
IL (1) IL252102B (es)
MX (1) MX381235B (es)
PT (1) PT3229810T (es)
SG (1) SG11201703979QA (es)
SI (2) SI3229810T1 (es)
TW (1) TWI576341B (es)
WO (1) WO2016081203A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107708702A (zh) * 2014-11-17 2018-02-16 塞勒克塔生物科学有限公司 磷脂醚类似物作为靶向癌症的药物载体
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
CA2998528A1 (en) 2015-09-22 2017-03-30 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
CN108430520B (zh) * 2015-11-06 2021-08-13 威斯康星校友研究基金会 长效钆基肿瘤靶向成像与治疗剂
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US11147823B2 (en) 2016-07-13 2021-10-19 Wisconsin Alumni Research Foundation Phospholipid ether analogs for imaging and targeted treatment of pediatric solid tumors
EP3484513B1 (en) 2016-07-18 2023-06-07 Wisconsin Alumni Research Foundation Radiohalogenated agents for combined cancer therapy
US11633506B2 (en) 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
IL264365B2 (en) 2016-07-25 2026-03-01 Wisconsin Alumni Res Found Chelates for targeted radiotherapy for in situ immune-modulated cancer vaccination
JP7127014B2 (ja) * 2016-07-25 2022-08-29 ウイスコンシン アラムナイ リサーチ ファウンデーシヨン 癌のイメージングおよび治療のための放射性リン脂質金属キレート
CN110612119B (zh) * 2017-02-07 2024-10-29 西雅图儿童医院（Dba西雅图儿童研究所） 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞の使用方法
SG11202007426XA (en) * 2018-02-06 2020-09-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
KR102821508B1 (ko) 2018-04-10 2025-06-16 셀렉타 바이오사이언시스, 인코퍼레이티드 인지질-플라베글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법
JP2022525400A (ja) * 2019-03-13 2022-05-13 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） フルオレセインエーテルリン脂質またはフルオレセインエーテルリン脂質前駆体と併用した抗フルオレセインｃａｒ ｔ細胞に対する拮抗薬としてのフルオレセインナトリウム
TWI705813B (zh) 2019-05-24 2020-10-01 國立交通大學 含有ganetespib的粒子與含有該粒子的藥學組成物及其在抗癌治療上的用途
US20220228096A1 (en) * 2019-06-27 2022-07-21 Showa Denko Materials Co., Ltd. Cell Scaffold Material, Cell Culture Support, and Cell Culture Method
CA3150991A1 (en) * 2019-09-12 2021-03-18 Cellectar Biosciences, Inc. Phospholipid ether conjugates as cancer-targeting drug vehicles
CA3154192A1 (en) * 2019-10-10 2021-04-15 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
AU2021217003A1 (en) 2020-02-04 2022-09-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Anti-dinitrophenol chimeric antigen receptors
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer
EP4326246A4 (en) 2021-04-23 2026-04-15 Wisconsin Alumni Res Found PSMA-TARGETING LIGANDS WITH OPTIMAL IMAGING AND THERAPY PROPERTIES
CN114437128B (zh) * 2022-01-28 2023-12-19 中国科学院长春应用化学研究所 一种胆碱磷酸修饰的紫杉醇药物及其制备方法和应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965391A (en) * 1987-10-23 1990-10-23 The University Of Michigan Radioiodinated phospholipid ether analogues
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
DE4408011C1 (de) 1994-03-10 1995-11-02 Max Delbrueck Centrum Pharmazeutisches Mittel zur Tumortherapie
US5534499A (en) * 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
CA2276284C (en) * 1996-12-04 2006-10-10 The Regents Of The University Of Michigan Radioiodinated phospholipid ether analogs and methods of using the same
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US7060290B1 (en) * 1999-02-18 2006-06-13 Supergen, Inc. Phosphocholine linked prodrug derivatives
IL131887A0 (en) * 1999-09-14 2001-03-19 Dpharm Ltd Phospholipid prodrugs of anti-proliferative drugs
US7700075B2 (en) 2004-07-08 2010-04-20 Cellectar, Llc Virtual colonoscopy with radiolabeled phospholipid ether analogs
US7632644B2 (en) 2004-03-02 2009-12-15 Cellectar, Inc. Imaging and selective retention of phospholipid ether analogs
KR20070015518A (ko) 2004-03-02 2007-02-05 셀렉타, 엘엘씨 암의 진단 및 치료를 위한 포스포리피드 유사체
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
KR20080005178A (ko) 2004-12-20 2008-01-10 셀렉타, 엘엘씨 암 검출 및 치료용 인지질 에테르 동족체
UA99434C2 (ru) 2005-12-19 2012-08-27 Аетерна Центаріс Гмбх Применение производных алкилфосфолипидов со сниженной цитотоксичностью
US7893286B2 (en) 2007-06-01 2011-02-22 Cellectar, Inc. Method for the synthesis of phospholipid ethers
US8022235B2 (en) * 2007-06-01 2011-09-20 Cellectar, Inc. Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use
US8486924B2 (en) 2007-11-28 2013-07-16 Celator Pharmaceuticals, Inc. Taxane delivery system
US20100286510A1 (en) * 2009-05-11 2010-11-11 Pinchuk Anatoly Use of fluorescent phospholipid ether compounds in biopsies
US20100284931A1 (en) * 2009-05-11 2010-11-11 Pinchuk Anatoly Fluorescent phospholipid ether compounds, compositions, and methods of use
ES2549459T3 (es) 2009-05-11 2015-10-28 Cellectar, Inc. Compuestos de éter de fosfolípido fluorescentes, composiciones y procedimientos de uso
US7811548B1 (en) 2009-05-11 2010-10-12 Cellectar, Inc. Fluorescent phospholipid ether compounds and compositions
US8871181B2 (en) 2009-05-11 2014-10-28 Cellectar, Inc. Fluorescent phospholipid ether compounds, compositions, and methods of use
SI3708192T1 (sl) 2009-06-12 2023-12-29 Cellectar, Inc. Eter fosfolipidne spojine za zdravljenje raka in slikanje in detekcijo rakavih izvornih celic
EP2475400A2 (en) 2009-09-11 2012-07-18 Cellectar, Inc. Non-radioactive phospholipid compounds, compositions, and methods of use
US20140255432A1 (en) 2011-07-27 2014-09-11 Ohio State Innovation Foundation Silvestrol, silvestrol analogs and uses thereof
CN107708702A (zh) * 2014-11-17 2018-02-16 塞勒克塔生物科学有限公司 磷脂醚类似物作为靶向癌症的药物载体
EP3888658B1 (en) 2015-11-25 2023-12-27 Effector Therapeutics, Inc. Eif4-a-inhibiting compounds and methods related thereto
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
KR102821508B1 (ko) 2018-04-10 2025-06-16 셀렉타 바이오사이언시스, 인코퍼레이티드 인지질-플라베글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법

Also Published As

Publication number Publication date
EP3750545A1 (en) 2020-12-16
KR20170106304A (ko) 2017-09-20
ES2978534T3 (es) 2024-09-13
TW201619145A (zh) 2016-06-01
US9925269B2 (en) 2018-03-27
TWI576341B (zh) 2017-04-01
EP3229810B1 (en) 2020-07-22
US20160136290A1 (en) 2016-05-19
KR102500181B1 (ko) 2023-02-14
EA037519B1 (ru) 2021-04-07
BR112017010188A2 (pt) 2018-02-14
US11439709B2 (en) 2022-09-13
ES2811367T3 (es) 2021-03-11
WO2016081203A2 (en) 2016-05-26
IL252102A0 (en) 2017-08-31
MX381235B (es) 2025-03-12
EP3750545B1 (en) 2024-03-27
EP3229810A2 (en) 2017-10-18
CA2968145C (en) 2023-06-27
CN116655690A (zh) 2023-08-29
CN107708702A (zh) 2018-02-16
SI3750545T1 (sl) 2024-06-28
EP3229810A4 (en) 2018-07-25
SG11201703979QA (en) 2017-06-29
US20160136190A1 (en) 2016-05-19
WO2016081203A3 (en) 2016-08-18
AU2015350400B2 (en) 2020-11-05
CA2968145A1 (en) 2016-05-26
IL252102B (en) 2021-10-31
EA201791094A1 (ru) 2017-09-29
PT3229810T (pt) 2020-08-27
DK3750545T3 (da) 2024-04-22
US20160228564A1 (en) 2016-08-11
BR112017010188B1 (pt) 2023-03-28
US20180333498A1 (en) 2018-11-22
US9480754B2 (en) 2016-11-01
JP6832861B2 (ja) 2021-02-24
NZ731669A (en) 2021-02-26
US9345718B1 (en) 2016-05-24
SI3229810T1 (sl) 2021-01-29
AU2015350400A1 (en) 2017-05-25
DK3229810T3 (da) 2020-08-17
JP2017535608A (ja) 2017-11-30

Similar Documents

Publication Publication Date Title
MX2017006382A (es) Analogos de eter fosfolipidico como portadores de farmacos dirigidos a cancer.
ECSP24026455A (es) Compuestos de pirrolotriazina como inhibidores de tam
CL2018000952A1 (es) Compuestos útiles como inmunomoduladores
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
BR112016023558A2 (pt) compostos úteis como imunomoduladores
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
PE20150887A1 (es) Compuestos de benceno sustituidos
AR091837A1 (es) Compuestos para inmunoterapia dirigida
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
MX2015012427A (es) Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer.
CR20150370A (es) Compuestos antivirales
CR20160072A (es) Compuestos y composiciones como inhibidores de la mek
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
DOP2016000094A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4.
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
MX377552B (es) Proceso para preparar un compuesto antiviral de formula i.
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
CO2018004581A2 (es) Compuestos de criptoficina y productos conjugados, y sus métodos de preparación
CL2015002027A1 (es) Compuestos quimicos
BR112014028042A2 (pt) inibidores de nampt
CO7101239A2 (es) Composiciones derivadas de la quitosana
BR112012023836A2 (pt) composto tricíclicos e inibidores de pbk contendo os mesmos
CL2017002304A1 (es) Métodos para tratar enfermedades
MX373636B (es) Compuestos de azetidiniloxifenilpirrolidina.